Pet Safety / Compounds / Duloxetine (Cymbalta)

Is Duloxetine (Cymbalta) safe for dogs and cats?

Moderate risk for pets

Duloxetine toxicity in dogs follows the SNRI pattern — serotonin syndrome is the primary concern with noradrenergic cardiovascular effects as a secondary component; the overall toxicity profile is intermediate between sertraline and venlafaxine in clinical severity. Toxic dose: clinical signs expected at ~5–15 mg/kg; moderate-severe serotonin syndrome at >15 mg/kg. Signs: typical serotonin syndrome (hyperthermia, tremors, mydriasis, hyperreflexia, hypersalivation), tachycardia, possible hypertension; agitation and vocalization. Delayed-release capsule: the enteric-coated pellets in duloxetine capsules may delay GI absorption; gastric decontamination (emesis) is effective if administered early (within 1–2 hours) before pellets move to the small intestine. CYP differences: dogs metabolize duloxetine differently from humans (CYP1A2 is less important in canine metabolism); metabolic profile means half-life may differ, affecting monitoring duration. Hepatotoxic potential: the hepatotoxic risk present in humans has unknown relevance to single-dose canine toxicity; LFT monitoring in dogs recovering from large exposures is prudent. Treatment: same SNRI protocol — cyproheptadine, methocarbamol, thermoregulation, IV fluids; prazosin for hypertension if needed.

What is duloxetine (cymbalta)?

The IUPAC name is (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine.

Also known as: (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine, duloxetine, (S)-Duloxetine, Yentreve.

IUPAC name
(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
CAS number
116539-59-4
Molecular formula
C18H19NOS
Molecular weight
297.4 g/mol
SMILES
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
PubChem CID
60835

Risk for dogs

Moderate risk

Duloxetine toxicity in dogs follows the SNRI pattern — serotonin syndrome is the primary concern with noradrenergic cardiovascular effects as a secondary component; the overall toxicity profile is intermediate between sertraline and venlafaxine in clinical severity. Toxic dose: clinical signs expected at ~5–15 mg/kg; moderate-severe serotonin syndrome at >15 mg/kg. Signs: typical serotonin syndrome (hyperthermia, tremors, mydriasis, hyperreflexia, hypersalivation), tachycardia, possible hypertension; agitation and vocalization. Delayed-release capsule: the enteric-coated pellets in duloxetine capsules may delay GI absorption; gastric decontamination (emesis) is effective if administered early (within 1–2 hours) before pellets move to the small intestine. CYP differences: dogs metabolize duloxetine differently from humans (CYP1A2 is less important in canine metabolism); metabolic profile means half-life may differ, affecting monitoring duration. Hepatotoxic potential: the hepatotoxic risk present in humans has unknown relevance to single-dose canine toxicity; LFT monitoring in dogs recovering from large exposures is prudent. Treatment: same SNRI protocol — cyproheptadine, methocarbamol, thermoregulation, IV fluids; prazosin for hypertension if needed.

Regulatory consensus

1 regulatory bodyhas classified Duloxetine (Cymbalta).

AgencyYearClassificationNotes
FDA—ApprovedApproved for MDD, GAD, DPNP, fibromyalgia, and chronic musculoskeletal pain

Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.

Where pets encounter duloxetine (cymbalta)

  • Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
  • Occupational Environments — Factories, Warehouses, Transportation vehicles

Safer alternatives

Lower-risk approaches that achieve a similar outcome to Duloxetine (Cymbalta):

  • Alternative drug class; Non-pharmacological therapy; Lowest effective dose
    Trade-offs: Direct chemical substitution requires verification that the replacement does not introduce new hazards (regrettable substitution). Conduct full hazard assessment of proposed alternative before adoption.
    Relative cost: 1.2-2×

Frequently asked questions

Is duloxetine (cymbalta) safe for pets?

Duloxetine toxicity in dogs follows the SNRI pattern — serotonin syndrome is the primary concern with noradrenergic cardiovascular effects as a secondary component; the overall toxicity profile is intermediate between sertraline and venlafaxine in clinical severity. Toxic dose: clinical signs expected at ~5–15 mg/kg; moderate-severe serotonin syndrome at >15 mg/kg. Signs: typical serotonin syndrome (hyperthermia, tremors, mydriasis, hyperreflexia, hypersalivation), tachycardia, possible hypertension; agitation and vocalization. Delayed-release capsule: the enteric-coated pellets in duloxetine capsules may delay GI absorption; gastric decontamination (emesis) is effective if administered early (within 1–2 hours) before pellets move to the small intestine. CYP differences: dogs metabolize duloxetine differently from humans (CYP1A2 is less important in canine metabolism); metabolic profile means half-life may differ, affecting monitoring duration. Hepatotoxic potential: the hepatotoxic risk present in humans has unknown relevance to single-dose canine toxicity; LFT monitoring in dogs recovering from large exposures is prudent. Treatment: same SNRI protocol — cyproheptadine, methocarbamol, thermoregulation, IV fluids; prazosin for hypertension if needed.

What products contain duloxetine (cymbalta)?

Duloxetine (Cymbalta) appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).

See Duloxetine (Cymbalta) in the pets app

Look up products containing duloxetine (cymbalta), compare to alternatives, and explore the full data record.

Open in pets View raw API data

Sources (2)
  1. FDA Prescribing Information: Duloxetine (Cymbalta) — MDD/GAD/DPNP/fibromyalgia/chronic pain; hepatotoxicity warning; urinary hesitancy; CYP1A2 substrate; discontinuation syndrome; pediatric GAD ≥7yr; alcohol contraindication; delayed-release formulation (2023) (2023) — regulatory
  2. ASPCA Animal Poison Control Center: SNRI Toxicosis in Dogs — venlafaxine extended-release pellets; dual serotonin/norepinephrine toxidrome; toxic dose thresholds; cardiac effects; intensive care management; fatality risk (2023) (2023) — veterinary

Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →